Ventana licenses CSTís personalized cancer diagnostics reagents
DANVERS, Mass.óCell Signaling Technology Inc. (CST) has granted Ventana Medical Systems Inc. a worldwide non-exclusive license to CST's patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor (EGFR) mutations for the field of tissue-based in-vitro diagnostic testing. Mutant forms of EGFR are important determinants in the clinical management of lung cancer. CST has developed and clinically validated mutation-specific EGFR antibodies through its internal Cancer Biomarker Program. CST says the company is pleased to see its focused cancer research efforts and antibody technology "applied to significant unmet needs in the diagnosis and treatment of cancer patients."
"CST is very excited to enter into this agreement with Ventana for the development of next- generation diagnostic products that intend to fulfill the promise of personalized cancer medicine," adds Dr. Michael J. Comb, CST's president and CEO.